Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dance Biopharm raises $9.5mm through sale of convertible debt and warrants

Executive Summary

Dance Biopharm Inc. (inhaled insulin for diabetes) raised $9.5mm through the sale of convertible notes and warrants to a syndicate of institutional investors and individuals. SternAegis Ventures (through Aegis Capital) was the placement agent. Funds will support ongoing late-stage trials of its Dance501 pocket-sized inhaler device.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies